B7-H4 Mediated Immune Regulation in Cancer Systems

B7-H4 is a member of the B7 family of immunoregulatory ligands that acts as a potent inhibitory checkpoint within the tumour microenvironment. Unlike PD-L1, its receptor remains unidentified, yet its engagement on T cells dampens cytotoxic responses, facilitating immune evasion. Tumour cells exploit B7-H4 through multiple layers of regulation, including post-translational modifications and proteolytic pathways, to sustain surface expression and suppress antitumour immunity. Soluble and extracellular vesicle–associated forms of B7-H4 further modulate systemic immune surveillance and can serve as prognostic biomarkers across diverse malignancies. Elevated expression of B7-H4 is widely observed in breast, ovarian, lung, cholangiocarcinoma and gastric tumours, correlating closely with advanced stage, chemotherapy resistance and reduced survival. Recent mechanistic insights have revealed targets for therapeutic intervention, such as palmitoylation enzymes, deubiquitinases and combination strategies with antibody–drug conjugates. These advances lay the groundwork for novel treatment paradigms aimed at dismantling B7-H4–mediated immunosuppression and restoring effective antitumour T cell responses.

Research from Nature Portfolio

Recent studies have uncovered a critical post-translational mechanism by which tumour cells sustain B7-H4–mediated immunosuppression. It was shown that a specific palmitoyltransferase attaches palmitate residues to a conserved cysteine of B7-H4, preventing its lysosomal degradation and thereby preserving its inhibitory function on T cells. Importantly, this modification can be pharmacologically targeted: a clinically approved CDK4/6 inhibitor was found to activate lysosomal pathways that degrade B7-H4 independently of cell-cycle effects. In preclinical tumour models, treatment with this agent led to marked T cell activation and reduced tumour growth, suggesting a promising avenue for repurposing existing drugs to counteract B7-H4–driven immune escape.

B7-H4 Mediated Immune Regulation in Cancer Systems publication trend

The graph below shows the total number of articles in b7-h4 mediated immune regulation in cancer systems across all publications each year (not limited to Nature Index journals).

Technical terms

B7-H4: An inhibitory immune checkpoint ligand of the B7 family that suppresses T cell activation in the tumour environment.

Palmitoylation: A reversible post-translational lipid modification in which palmitate is covalently attached to cysteine residues, affecting protein stability and localisation.

Deubiquitinase: An enzyme that removes ubiquitin moieties from proteins, thereby preventing their proteasomal degradation.

Antibody–drug conjugate (ADC): A targeted cancer therapy comprising an antibody linked to a cytotoxic agent, designed to deliver the drug selectively to tumour cells.

Extracellular vesicle (EV): A membrane-bound particle released by cells that carries proteins, lipids and nucleic acids, and mediates intercellular communication.

Tumour microenvironment (TME): The complex milieu of malignant cells, immune cells, stromal elements and signalling molecules surrounding a tumour.

References

1. Palmitoylation prevents B7-H4 lysosomal degradation sustaining tumor immune evasion. Nature Communications (2025).
2. Tuning Immune‐Cold Tumor by Suppressing USP10/B7‐H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs. Advanced Science (2024).
3. The role of B7-H4 in ovarian cancer immunotherapy: current status, challenges, and perspectives. Frontiers in Immunology (2024).
4. Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cells (2023).
5. B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer. Cancer Cell International (2018).
6. Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma. Cell Death & Disease (2017).
7. Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer. World Journal of Surgical Oncology (2014).